Compare HTCR & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | LABT |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.2M |
| IPO Year | 2022 | 2026 |
| Metric | HTCR | LABT |
|---|---|---|
| Price | $1.77 | $0.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.1K | ★ 563.0K |
| Earning Date | 11-17-2026 | 11-18-2026 |
| Dividend Yield | ★ 145.25% | N/A |
| EPS Growth | ★ 414.29 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,407,229.00 | N/A |
| Revenue This Year | $118.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.15 | $0.76 |
| 52 Week High | $3.97 | $6.85 |
| Indicator | HTCR | LABT |
|---|---|---|
| Relative Strength Index (RSI) | 29.99 | 25.81 |
| Support Level | N/A | N/A |
| Resistance Level | $2.16 | $2.13 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 19.61 | 1.53 |
HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.